Top

Supportive Care in Cancer

Published in:

01-01-2016 | Review Article

Modifiable factors and cognitive dysfunction in breast cancer survivors: a mixed-method systematic review

Author: Ashley Henneghan

Published in: Supportive Care in Cancer | Issue 1/2016

Abstract

Purpose

It is unknown why some breast cancer survivors experience cancer-related cognitive impairments (CRCI) after cancer treatment, and modifiable risk factors for CRCI remain to be explicated. This mixed-method systematic review synthesizes quantitative and qualitative evidence for relationships between modifiable factors and CRCI in breast cancer survivors who receive chemotherapy as part of their treatment.

Methods

Keyword Searches of PubMed/Medline, PsychINFO, and CINAHL were performed for January 2005 through June 2015. Studies that provided data on associations between modifiable biological, behavioral, environmental, and psychosocial factors and cognition were included.

Results

Twenty-two quantitative studies and five qualitative studies were identified after applying inclusion and exclusion criteria yielding evidence for significant relationships among modifiable biological (inflammatory cytokines), behavioral (sleep quality, physical activity), and psychosocial (stress, distress, affect) factors and CRCI.

Conclusion

Many women unfortunately experience CRCI after breast cancer chemotherapy, with limited treatment options available to improve cognitive function. This review synthesizes current evidence to support the associations between modifiable factors and CRCI and can inform research to evaluate these factors prospectively. The clinical implications of these findings suggest that lifestyle factors such as physical activity, stress management, and sleep quality may be appropriate targets for behavioral interventions to improve cognitive function following breast cancer chemotherapy; however, further research is necessary.

American Cancer Society (2013) Breast cancer facts & figures 2013–2014. American Cancer Society, Atlanta

Janelsins MC, Kesler SR, Ahles TA, Morrow GR (2014) Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry 26(1):102–113. doi:10.3109/09540261.2013.864260 PubMedCentralCrossRefPubMed

Wefel JS, Schagen SB (2012) Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 12(3):267–275. doi:10.1007/s11910-012-0264-9 CrossRefPubMed

Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv 3(4):223–232. doi:10.1007/s11764-009-0098-x PubMedCentralCrossRefPubMed

Ganz PA, Bower JE, Kwan L, Castellon SA, Silverman DH, Geist C et al (2013) Does tumor necrosis factor-alpha (TNF-alpha) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun 30(Suppl):S99–S108. doi:10.1016/j.bbi.2012.07.015 PubMedCentralCrossRefPubMed

Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA (2004) ‘Chemobrain’ in breast carcinoma?: a prologue. Cancer 101(3):466–475. doi:10.1002/cncr.20393 CrossRefPubMed

Reid-Arndt SA (2009) Breast cancer and “chemobrain”: the consequences of cognitive difficulties following chemotherapy and the potential for recovery. Mo Med 106(2):127–131PubMed

Ottati A, Feuerstein M (2013) Brief self-report measure of work-related cognitive limitations in breast cancer survivors. J Cancer Surviv 7(2):262–273. doi:10.1007/s11764-013-0275-9 CrossRefPubMed

Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH et al (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30(29):3578–3587. doi:10.1200/jco.2011.39.5640 PubMedCentralCrossRefPubMed

10.

Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J (2005) A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104(10):2222–2233. doi:10.1002/cncr.21469 CrossRefPubMed

11.

Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T (2013) A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 39(3):297–304. doi:10.1016/j.ctrv.2012.11.001 CrossRefPubMed

12.

Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38(7):926–934. doi:10.1016/j.ctrv.2012.05.002 CrossRefPubMed

13.

McDonald BC et al (2012) Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol 30(20):2500–2508PubMedCentralCrossRefPubMed

14.

Kesler SR (2014) Default mode network as a potential biomarker of chemotherapy-related brain injury. Neurobiol Aging 35(Suppl 2):S11–S19CrossRefPubMed

15.

de Ruiter MB, Schagen SB (2013) Functional MRI studies in non-CNS cancers. Brain Imaging Behav 7(4):388–408CrossRefPubMed

16.

Holohan KN, Von Ah D, McDonald BC, Saykin AJ (2013) Neuroimaging, cancer, and cognition: state of the knowledge. Semin Oncol Nurs 29(4):280–287. doi:10.1016/j.soncn.2013.08.008 CrossRefPubMed

17.

Saykin AJ, de Ruiter MB, McDonald BC, Deprez S, Silverman DH (2013) Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research. Brain Imaging Behav 7(4):363–373. doi:10.1007/s11682-013-9283-7 PubMedCentralCrossRefPubMed

18.

Ahles TA, Saykin AJ (2007) Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7(3):192–201PubMedCentralCrossRefPubMed

19.

Vardy J (2009) Cognitive function in breast cancer survivors. Cancer Treat Res 151:387–419CrossRefPubMed

20.

Janelsins MC et al (2011) An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol 38(3):431–438PubMedCentralCrossRefPubMed

21.

Ahles TA, Root JC, Ryan EL (2012) Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 30(30):3675–3686. doi:10.1200/jco.2012.43.0116 PubMedCentralCrossRefPubMed

22.

Arndt J, Das E, Schagen SB, Reid-Arndt SA, Cameron LD, Ahles TA (2013) Broadening the cancer and cognition landscape: the role of self-regulatory challenges. Psychooncology. doi:10.1002/pon.3351 PubMedCentral

23.

Mandelblatt JS, Stern RA, Luta G, McGuckin M, Clapp JD, Hurria A et al (2014) Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J Clin Oncol 32(18):1909–1918. doi:10.1200/JCO.2013.54.2050 PubMedCentralCrossRefPubMed

24.

Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS et al (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28(29):4434–4440. doi:10.1200/jco.2009.27.0827 PubMedCentralCrossRefPubMed

25.

Ahles TA, Saykin AJ, Noll WW, Furstenberg CT, Guerin S, Cole B et al (2003) The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12(6):612–619. doi:10.1002/pon.742 CrossRefPubMed

26.

Andreano JM, Waisman J, Donley L, Cahill L (2012) Effects of breast cancer treatment on the hormonal and cognitive consequences of acute stress. Psychooncology 21(10):1091–1098. doi:10.1002/pon.2006 CrossRefPubMed

27.

Minisini A, Atalay G, Bottomley A, Puglisi F, Piccart M, Biganzoli L (2004) What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol 5(5):273–282. doi:10.1016/S1470-2045(04)01465-2 CrossRefPubMed

28.

Wefel JS, Witgert ME, Meyers CA (2008) Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev 18(2):121–131. doi:10.1007/s11065-008-9058-x CrossRefPubMed

29.

Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FS (2006) Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 98(23):1742–1745. doi:10.1093/jnci/djj470 CrossRefPubMed

30.

Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM et al (2010) Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol 76(2):133–141. doi:10.1016/j.critrevonc.2009.11.001 CrossRefPubMed

31.

Poppelreuter M, Weis J, Kulz AK, Tucha O, Lange KW, Bartsch HH (2004) Cognitive dysfunction and subjective complaints of cancer patients. A cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 40(1):43–49CrossRefPubMed

32.

Pullens MJ, De Vries J, Roukema JA (2010) Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology 19(11):1127–1138. doi:10.1002/pon.1673 CrossRefPubMed

33.

Asher A (2011) Cognitive dysfunction among cancer survivors. Am J Phys Med Rehabil 90(5 Suppl 1):S16–S26. doi:10.1097/PHM.0b013e31820be463 CrossRefPubMed

34.

Bower JE, Lamkin DM (2013) Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun 30(Suppl):S48–S57. doi:10.1016/j.bbi.2012.06.011 PubMedCentralCrossRefPubMed

35.

Cheung YT, Lim SR, Ho HK, Chan A (2013) Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future research. PLoS One 8(12), e81234. doi:10.1371/journal.pone.0081234 PubMedCentralCrossRefPubMed

36.

Kang DH, Rice M, Park NJ, Turner-Henson A, Downs C (2010) Stress and inflammation: a biobehavioral approach for nursing research. West J Nurs Res 32(6):730–760. doi:10.1177/0193945909356556 CrossRefPubMed

37.

Pluye P, Gagnon MP, Griffiths F, Johnson-Lafleur J (2009) A scoring system for appraising mixed methods research, and concomitantly appraising qualitative, quantitative and mixed methods primary studies in Mixed Studies Reviews. Int J Nurs Stud 46(4):529–546. doi:10.1016/j.ijnurstu.2009.01.009 CrossRefPubMed

38.

Donovan LA, Wakefield CE, Russell V, Cohn RJ (2015) Hospital-based bereavement services following the death of a child: a mixed study review. Palliat Med 29(3):193–210. doi:10.1177/0269216314556851 CrossRefPubMed

39.

Khanassov V, Vedel I, Pluye P (2014) Barriers to implementation of case management for patients with dementia: a systematic mixed studies review. Ann Fam Med 12(5):456–465. doi:10.1370/afm.1677 PubMedCentralCrossRefPubMed

40.

Whittemore R, Jaser S, Chao A, Jang M, Grey M (2012) Psychological experience of parents of children with type 1 diabetes: a systematic mixed-studies review. Diabetes Educ 38(4):562–579. doi:10.1177/0145721712445216 PubMedCentralCrossRefPubMed

41.

Cheung YT et al (2015) Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study dagger. Ann Oncol. doi:10.1093/annonc/mdv206 PubMedCentral

42.

Conroy SK et al (2013) Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Res Treat 137(2):493–502PubMedCentralCrossRefPubMed

43.

Crowgey T, Peters KB, Hornsby WE, Lane A, McSherry F, Herndon JE 2nd et al (2014) Relationship between exercise behavior, cardiorespiratory fitness, and cognitive function in early breast cancer patients treated with doxorubicin-containing chemotherapy: a pilot study. Appl Physiol Nutr Metab 39(6):724–729. doi:10.1139/apnm-2013-0380 PubMedCentralCrossRefPubMed

44.

Pomykala KL, Ganz PA, Bower JE, Kwan L, Castellon SA, Mallam S et al (2013) The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav 7(4):511–523. doi:10.1007/s11682-013-9243-2 PubMedCentralCrossRefPubMed

45.

Chen ML, Miaskowski C, Liu LN, Chen SC (2012) Changes in perceived attentional function in women following breast cancer surgery. Breast Cancer Res Treat 131(2):599–606. doi:10.1007/s10549-011-1760-3 CrossRefPubMed

46.

Jaremka LM, Peng J, Bornstein R, Alfano CM, Andridge RR, Povoski SP et al (2014) Cognitive problems among breast cancer survivors: loneliness enhances risk. Psychooncology. doi:10.1002/pon.3544

47.

Kesler S, Janelsins M, Koovakkattu D, Palesh O, Mustian K, Morrow G et al (2013) Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun 30 Suppl:S109–S116. doi:10.1016/j.bbi.2012.05.017 CrossRefPubMed

48.

Kesler SR et al (2013) Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav 7(4):501–510CrossRefPubMed

49.

Sanford SD, Beaumont JL, Butt Z, Sweet JJ, Cella D, Wagner LI (2014) Prospective longitudinal evaluation of a symptom cluster in breast cancer. Pain Symptom Manage 47(4):721–730. doi:10.1016/j.jpainsymman.2013.05.010 CrossRef

50.

Vearncombe KJ et al (2009) Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 15(6):951–962CrossRefPubMed

51.

Cheung YT, Shwe M, Chui WK, Chay WY, Ang SF, Dent RA et al (2012) Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients. Ann Pharmacother 46(12):1645–1655. doi:10.1345/aph.1R408 CrossRefPubMed

52.

Myers JS, Wick JA, Klemp J (2015) Potential factors associated with perceived cognitive impairment in breast cancer survivors. Support Care Cancer. doi:10.1007/s00520-015-2708-7 PubMedCentral

53.

Li J et al (2015) Perceived cognitive impairment in Chinese patients with breast cancer and its relationship with post-traumatic stress disorder symptoms and fatigue. Psycho-Oncology 24(6):676–682CrossRefPubMed

54.

Janelsins MC, Mustian KM, Palesh OG, Mohile SG, Peppone LJ, Sprod LK et al (2012) Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer 20(4):831–839. doi:10.1007/s00520-011-1158-0 PubMedCentralCrossRefPubMed

55.

Mehlsen M et al (2009) No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology 18(3):248–257CrossRefPubMed

56.

Alvarez J, Meyer FL, Granoff DL, Lundy A (2013) The effect of EEG biofeedback on reducing postcancer cognitive impairment. Integr Cancer Ther 12(6):475–487. doi:10.1177/1534735413477192 CrossRefPubMed

57.

Hermelink K, Kuchenhoff H, Untch M, Bauerfeind I, Lux MP, Buhner M et al (2010) Two different sides of ‘chemobrain’: determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 19(12):1321–1328. doi:10.1002/pon.1695 CrossRefPubMed

58.

Phillips KA, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V et al (2010) Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 19(5):388–395. doi:10.1016/j.breast.2010.03.025 PubMedCentralCrossRefPubMed

59.

Schagen SB, Das E, van Dam FS (2009) The influence of priming and pre-existing knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients. Psycho-Oncology 18(6):674–678. doi:10.1002/pon.1454 CrossRefPubMed

60.

Myers JS (2012) Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum 39(1):E31–E40. doi:10.1188/12.onf.e31-e40 CrossRefPubMed

61.

Cheung YT et al (2012) Cognitive changes in multiethnic Asian breast cancer patients: a focus group study. Ann Oncol 23(10):2547–2552CrossRefPubMed

62.

Player L, Mackenzie L, Willis K, Loh SY (2014) Women’s experiences of cognitive changes or ‘chemobrain’ following treatment for breast cancer: a role for occupational therapy? Aust Occup Ther J. doi:10.1111/1440-1630.12113 PubMed

63.

Munir F, Kalawsky K, Lawrence C, Yarker J, Haslam C, Ahmed S (2011) Cognitive intervention for breast cancer patients undergoing adjuvant chemotherapy: a needs analysis. Cancer Nurs 34(5):385–392. doi:10.1097/NCC.0b013e31820254f3 CrossRefPubMed

64.

Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR (2008) Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 26(6):971–982. doi:10.1200/JCO.2007.10.7805 PubMedCentralCrossRefPubMed

65.

Seruga B, Zhang H, Bernstein LJ, Tannock IF (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8(11):887–899. doi:10.1038/nrc2507 CrossRefPubMed

66.

Ahles TA, Li Y, McDonald BC, Schwartz GN, Kaufman PA, Tsongalis GJ et al (2014) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking. Psychooncology. doi:10.1002/pon.3545

67.

Cheung YT, Chan A, Ng T et al (2014) The Association of Pro-inflammatory biomarkers and cognitive impairment in Asian breast cancer patients: a multi-centered, prospective, cohort study. International Cognition and Cancer Taskforce, Seattle

68.

Bherer L, Erickson KI, Liu-Ambrose T (2013) A review of the effects of physical activity and exercise on cognitive and brain functions in older adults. J Aging Res. doi:10.1155/2013/657508

69.

Aggarwal NT, Wilson RS, Beck TL, Rajan KB, Mendes de Leon CF, Evans DA et al (2014) Perceived stress and change in cognitive function among adults 65 years and older. Psychosom Med 76(1):80–85. doi:10.1097/PSY.0000000000000016 PubMedCentralCrossRefPubMed

70.

Reid-Arndt SA, Cox CR (2012) Stress, coping and cognitive deficits in women after surgery for breast cancer. J Clin Psychol Med Settings 19(2):127–137. doi:10.1007/s10880-011-9274-z CrossRefPubMed

71.

Kremen WS, Lachman ME, Pruessner JC, Sliwinski M, Wilson R (2012) Mechanisms of age-related cognitive change and targets for intervention: social interactions and stress. J Gerontol A Biol Sci Med Sci 67(7):760–765. doi:10.1093/gerona/gls125 PubMedCentralCrossRefPubMed

72.

Cacioppo JT, Hawkley LC (2009) Perceived social isolation and cognition. Trends Cogn Sci 13(10):447–454. doi:10.1016/j.tics.2009.06.005 PubMedCentralCrossRefPubMed

73.

Nelson WL, Suls J (2013) New approaches to understand cognitive changes associated with chemotherapy for non-central nervous system tumors. J Pain Symptom Manage. doi:10.1016/j.jpainsymman.2012 PubMedCentral

74.

Demark-Wahnefried W, Jones LW (2008) Promoting a healthy lifestyle among cancer survivors. Hematol Oncol Clin North Am 22(2):319–342PubMedCentralCrossRefPubMed

75.

Hewitt M, Greenfield S, Stovall E (2005) (ed) From cancer patient to cancer survivor: lost in transition. The National Academies Press

76.

Pekmezi DW, Demark-Wahnefried W (2011) Updated evidence in support of diet and exercise interventions in cancer survivors. Acta Oncol 50(2):167–178PubMedCentralCrossRefPubMed

77.

Parelkar P, Thompson NJ, Kaw CK, Miner KR, Stein KD (2013) Stress coping and changes in health behavior among cancer survivors: a report from the American Cancer Society’s Study of Cancer Survivors-II (SCS-II). J Psychosoc Oncol 31(2):136–152. doi:10.1080/07347332.2012.761322 CrossRefPubMed

78.

Blanchard CM, Courneya KS, Stein K (2008) Cancer survivors’ adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society’s SCS-II. J Clin Oncol 26(13):2198–2204. doi:10.1200/JCO.2007.14.6217 CrossRefPubMed

79.

Garland SN et al (2014) Sleeping well with cancer: a systematic review of cognitive behavioral therapy for insomnia in cancer patients. Neuropsychiatr Dis Treat 10:1113–1124PubMedCentralPubMed

Title: Modifiable factors and cognitive dysfunction in breast cancer survivors: a mixed-method systematic review
Author: Ashley Henneghan
Publication date: 01-01-2016
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 1/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-2927-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2016

Prevalence of severe depressive symptoms increases as death approaches and is associated with disease burden, tangible social support, and high self-perceived burden to others

Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France

Relationship between palliative care consultation service and end-of-life outcomes

Risk of thiamine deficiency and Wernicke’s encephalopathy after gastrointestinal surgery for cancer

Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study

Effects of a case management program on patients with oral precancerous lesions: a randomized controlled trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer